Health Condition 1: H269- Unspecified cataract
Conditions
Interventions
Intervention1: Nepafenac eyedrops: Group B- Nepafenac (0.1%) eye drops three times a day for 3 weeks
Intervention2: Nepafenac eyedrops: Group B- Nepafenac (0.1%) eye drops three times a day for 3 week
Sponsors
Pt B D Sharma PGIMS Rohtak
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients above 45 years of age with senile cataract undergoing phacoemulsification 2. Patients of either sex will be included 3. Patient willing to give written informed consent
Exclusion criteria
Exclusion criteria: 1. Patients with presenile cataract, glaucoma, uveitis, complicated cataract, subluxated cataract, traumatic cataract or posterior segment pathology 2. Patients sensitive to aspirin and other related NSAIDs 3. Use of systemic or topical steroids within 2 weeks of surgery 4. Use of systemic or topical NSAIDs within 7 days of surgery 5. Patient with uncontrolled diabetes 6. Any intraoperative complication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Change from baseline in Central corneal thickness post cataract surgery. 2. Resolution of anterior chamber reaction. 3. Improvement in visual acuity following cataract surgery.Timepoint: Patients will be evaluated at post-operative day 1, 1 week and 3 weeks. Any adverse drug reaction if occurs at any point in the study, has to be reported promptly and ADR monitoring to be done throughout the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change from baseline Intraocular pressure following cataract surgery. 2. Improvement in patient comfort post cataract surgery.Timepoint: Patients will be evaluated at post-operative day 1, 1 week and 3 weeks. | — |
Countries
India
Contacts
Public ContactDr Sumit Kumar
Pt. B D Sharma PGIMS Rohtak
Outcome results
None listed